Clinical Trial Results: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled crossover trial of atrasentan in IgA nephropathy completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Status: COMPLETED | Results posted: 2026-07-20